Ashley Shea
Primary Care · Cincinnati, OHNPI 1013474436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 40 manufacturers reported payments, led by AbbVie at 27.2% of the total. Among primary care clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$630
- Biohaven Pharmaceuticals, Inc.$213
- Lilly USA, LLC$205
- QOL Medical, LLC$203
- Biohaven Pharmaceutical Holding Company Ltd.$192
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,191100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$228
How this compares
$4,191 in reported general payments places this provider in the 90th percentile of 321 primary care providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 24 | $36,343 |
| MounjaroTirzepatide | 11 | $17,619 |
| MyrbetriqMirabegron | 12 | $5,560 |
| Bupropion XlBupropion Hcl | 51 | $1,041 |
| Estradiol (Twice Weekly)Estradiol | 12 | $987 |
| Quetiapine Fumarate | 11 | $607 |
| Levothyroxine Sodium | 39 | $298 |
| Atorvastatin Calcium | 28 | $283 |
| Duloxetine Hcl | 13 | $277 |
| Lisinopril | 52 | $253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $243 |
| Rosuvastatin Calcium | 29 | $240 |
| Gabapentin | 15 | $219 |
| Losartan Potassium | 31 | $180 |
| Ezetimibe | 12 | $176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $630 | $36,34324 claims |
| Lilly USA, LLCMounjaro | $205 | $17,61911 claims |
| Astellas Pharma US IncMyrbetriq | $177 | $5,56012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 321 primary care providers in Ohio.
Other primary care in Cincinnati
- Suzanne KahleCincinnati$4K
- Tiffany EscobarCincinnati$3K
- Adine EdwardsSpringfield$14K
- Kelly McKenna TaulbeeHamilton$12K
- Lindsay ChappellFairlawn$11K
- Laura HolligerNorth Canton$10K
- Caitlyn FrantzDayton$10K
- Brandy RichardsCleveland$8K
- Regan HeagenFindlay$8K
- Zachary HaleBeavercreek$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.